Then the phase 3OCEANIC-AF, trial comparing the novel factor XI inhibitor asundexian (Bayer) vs the direct-acting oral anticoagulant apixaban in patients with atrial fibrillation was stopped early for futility. What are the implications for factor XI as a target, and where does it leave the o...